SHCSotera Health Company

$19.54

Price

$19.54+74%1Y
1M+12%1Y+74%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average
8/10
Value45
Quality82
Momentum68
Growth56
Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world.

In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR

P/E (TTM)34.3
Market Cap$4.51B
1Y Return+74%
5Y Return-16%

Business segments

Q2 2026 · $258.8M

The company’s own SEC segment disclosure.

  • Sterigenics$211.6M82%
  • Nordion$47.2M18%

Sotera Health Company (SHC) reported revenue of $321M in Q2 2026 (quarter ended June 30, 2026), up 9.2% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $54M (17% of revenue). For the full year FY2025, revenue was $1.16B (+5.7% year on year) and net income $78M. Its largest segment in 2026-Q2 was Sterigenics at $212M, 82% of the disclosed total, just ahead of Nordion at 18%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.